

TABLE OF EXEMPT ANABOLIC STEROID PRODUCTS—Continued

Trade name	Company	NDC No.	Form	Ingredients	Quantity
Testosterone Cypionate—Estradiol Cypionate Injection.	Best Generics, No. Miami Beach, FL.	54274-530	Vial	Testosterone cypionate Estradiol cypionate	50 mg/ml 2 mg/ml
Testosterone Cypionate—Estradiol Cypionate Injection.	Goldline Labs, Ft. Lauderdale, FL.	0182-3069	Vial	Testosterone cypionate Estradiol cypionate	50 mg/ml. 2 mg/ml.
Testosterone Cypionate—Estradiol Cypionate Injection.	Schein Pharmaceuticals, Port Washington, NY.	0364-6611	Vial	Testosterone cypionate Estradiol cypionate	50 mg/ml 2 mg/ml
Testosterone Cypionate—Estradiol Cypionate Injection.	Steris Labs. Inc., Phoenix, AZ.	0402-0257	Vial	Testosterone cypionate Estradiol cypionate	50 mg/ml 2 mg/ml
Testosterone Cypionate—Estradiol Cypionate Injection.	The Upjohn Co., Kalamazoo, MI.	0009-0253	Vial	Testosterone cypionate Estradiol cypionate	50 mg/ml. 2 mg/ml.
Testosterone Enanthate—Estradiol Valerate Injection.	Goldline Labs, Ft. Lauderdale, FL.	0182-3073	Vial	Testosterone enanthate Estradiol valerate	90 mg/ml. 4 mg/ml.
Testosterone Enanthate—Estradiol Valerate Injection.	Schein Pharmaceuticals, Port Washington, NY.	0364-6618	Vial	Testosterone enanthate Estradiol valerate	90 mg/ml 4 mg/ml
Testosterone Enanthate—Estradiol Valerate Injection.	Steris Labs. Inc., Phoenix, AZ.	0402-0360	Vial	Testosterone enanthate Estradiol valerate	90 mg/ml 4 mg/ml
Tilapia Sex Reversal Feed (Investigational).	Zeigler Brothers, Inc., Gardners, PA.	Plastic Bags.	Methyltestosterone fish feed.	60 mg/1 kg.

[56 FR 42937, Aug. 30, 1991, as amended at 57 FR 55091, Nov. 24, 1992; 58 FR 16773, Mar. 31, 1993; 58 FR 34708, June 29, 1993]

HEARINGS

§ 1308.41 Hearings generally.

In any case where the Administrator shall hold a hearing on the issuance, amendment, or repeal of rules pursuant to section 201 of the Act, the procedures for such hearing and accompanying proceedings shall be governed generally by the rulemaking procedures set forth in the Administrative Procedure Act (5 U.S.C. 551-559) and specifically by section 201 of the Act (21 U.S.C. 811), by §§ 1308.42-1308.51, and by §§ 1316.41-1316.67 of this chapter.

§ 1308.42 Purpose of hearing.

If requested by any interested person after proceedings are initiated pursuant to § 1308.44, the Administrator shall hold a hearing for the purpose of receiving factual evidence and expert opinion regarding the issues involved in the issuance, amendment or repeal of a rule issuable pursuant to section 201(a) of the Act (21 U.S.C. 811(a)). Extensive argument should not be offered into evidence but rather presented in opening or closing statements of counsel or in memoranda or proposed findings of fact and conclusions of law.

§ 1308.43 Waiver or modification of Rules.

The Administrator or the presiding officer (with respect to matters pending before him) may modify or waive any rule in this part by notice in advance of the hearing, if he determines that no party in the hearing will be unduly prejudiced and the ends of justice will thereby be served. Such notice of modification or waiver shall be made a part of the record of the hearing.

§ 1308.44 Initiation of proceedings for rulemaking.

(a) Any interested person may submit a petition to initiate proceedings for the issuance, amendment, or repeal of any rule or regulation issuable pursuant to the provisions of section 201 of the Act.

(b) Petitions shall be submitted in quintuplicate to the Administrator in the following form:

 (Date)
 ADMINISTRATOR, DRUG ENFORCEMENT
 ADMINISTRATION
 Department of Justice,
 Washington, DC 20537.